{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:16:48Z","timestamp":1792700208533,"version":"4.5.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T00:00:00Z","timestamp":1677196800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016957","name":"Mirati Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016957","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.jtho.2023.02.016","type":"journal-article","created":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T19:43:56Z","timestamp":1677267836000},"page":"907-921","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy"],"prefix":"10.1016","volume":"18","author":[{"given":"Kai","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Berz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirish M.","family":"Gadgeel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wade T.","family":"Iams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debora S.","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Collin M.","family":"Blakely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander I.","family":"Spira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish R.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Waterhouse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald A.","family":"Richards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Jotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward B.","family":"Garon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Traynor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Olson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Latven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Shazer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ticiana A.","family":"Leal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2023.02.016_bib1","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in Advanced nonsquamous non\u2013small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2023.02.016_bib2","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non\u2013small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2023.02.016_bib3","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1\u2013positive non\u2013small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2023.02.016_bib4","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.annonc.2021.04.008","article-title":"Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189","volume":"32","author":"Rodr\u00edguez-Abreu","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2023.02.016_bib5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ejhpharm-2021-002803","article-title":"Efficacy and safety of PD-1\/PD-L1 plus CTLA-4 antibodies \u00b1 other therapies in lung cancer: a systematic review and meta-analysis","volume":"30","author":"Shen","year":"2023","journal-title":"Eur J Hosp Pharm"},{"key":"10.1016\/j.jtho.2023.02.016_bib6","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1038\/s41591-022-01977-y","article-title":"Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial","volume":"28","author":"Gogishvili","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jtho.2023.02.016_bib7","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1200\/JCO.22.00975","article-title":"Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non\u2013small-cell lung cancer: the phase III POSEIDON study","volume":"41","author":"Johnson","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2023.02.016_bib8","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","article-title":"First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial","volume":"22","author":"Paz-Ares","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2023.02.016_bib9","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2023.02.016_bib10","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","article-title":"Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"West","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2023.02.016_bib11","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non\u2013small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2023.02.016_bib12","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ccell.2020.03.017","article-title":"Acquired resistance to immune checkpoint inhibitors","volume":"37","author":"Schoenfeld","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jtho.2023.02.016_bib13","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1158\/2159-8290.CD-20-1638","article-title":"Overcoming resistance to tumor-targeted and\u00a0immune-targeted therapies","volume":"11","author":"Aldea","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2023.02.016_bib14","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41422-020-0337-2","article-title":"The future of cancer immunotherapy: microenvironment-targeting combinations","volume":"30","author":"Murciano-Goroff","year":"2020","journal-title":"Cell Res"},{"key":"10.1016\/j.jtho.2023.02.016_bib15","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1200\/EDBK_237987","article-title":"Reprogramming the tumor microenvironment to improve immunotherapy: emerging strategies and combination therapies","volume":"39","author":"Datta","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.jtho.2023.02.016_bib16","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/imr.12522","article-title":"TAM receptor tyrosine kinases as emerging targets of innate immune checkpoint blockade for cancer therapy","volume":"276","author":"Akalu","year":"2017","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jtho.2023.02.016_bib17","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.124184","article-title":"Sitravatinib potentiates immune checkpoint blockade in refractory cancer models","volume":"3","author":"Du","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.jtho.2023.02.016_bib18","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrc3847","article-title":"The TAM family: phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer","volume":"14","author":"Graham","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jtho.2023.02.016_bib19","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3390\/cancers8100097","article-title":"The role of TAM family receptors in immune cell function: implications for cancer therapy","volume":"8","author":"Paolino","year":"2016","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtho.2023.02.016_bib20","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1186\/s12935-021-02089-2","article-title":"New insights into M1\/M2 macrophages: key modulators in cancer progression","volume":"21","author":"Liu","year":"2021","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.jtho.2023.02.016_bib21","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.1158\/1078-0432.CCR-18-1543","article-title":"The intersection between tumor angiogenesis and immune suppression","volume":"25","author":"Rahma","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2023.02.016_bib22","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1007\/s10637-022-01274-y","article-title":"First-in-human phase 1\/1b study to evaluate sitravatinib in patients with advanced solid tumors","volume":"40","author":"Bauer","year":"2022","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.jtho.2023.02.016_bib23","article-title":"Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity study","volume":"9","author":"Oliva","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"issue":"15_suppl","key":"10.1016\/j.jtho.2023.02.016_bib24","article-title":"SNOW: sitravatinib and nivolumab in oral cavity cancer (OCC) window of opportunity study","volume":"38","author":"Bernal","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl","key":"10.1016\/j.jtho.2023.02.016_bib25","doi-asserted-by":"crossref","first-page":"S373","DOI":"10.1016\/j.jtho.2022.07.642","article-title":"EP08.01-070 Safety and efficacy of sitravatinib\u00a0+ tislelizumab in patients with PD-L1+, locally advanced\/metastatic, squamous NSCLC","volume":"17","author":"Zhao","year":"2022","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2023.02.016_bib27","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1200\/JCO.2012.45.7903","article-title":"Modified toxicity probability interval design: a safer and more reliable method than the 3+ 3 design for practical phase I trials","volume":"31","author":"Ji","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2023.02.016_bib29","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.jtho.2023.02.016_bib30","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1177\/1740774508089279","article-title":"A\u00a0predictive probability design for phase II cancer clinical trials","volume":"5","author":"Lee","year":"2008","journal-title":"Clin Trials"},{"key":"10.1016\/j.jtho.2023.02.016_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0008972","article-title":"CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases","volume":"5","author":"Tan","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.jtho.2023.02.016_bib32","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920937902","article-title":"Resistance to immune checkpoint inhibitors in non-small cell lung cancer: biomarkers and therapeutic strategies","volume":"12","author":"Walsh","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.jtho.2023.02.016_bib33","article-title":"Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce","volume":"8","author":"Kluger","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.jtho.2023.02.016_bib34","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/j.annonc.2021.08.2151","article-title":"Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer","volume":"32","author":"Schoenfeld","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2023.02.016_bib35","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.2217\/fon-2021-0862","article-title":"Immunotherapy-based combination strategies for treatment of EGFR-TKI-resistant non-small-cell lung cancer","volume":"18","author":"Chen","year":"2022","journal-title":"Future Oncol"},{"issue":"suppl 18","key":"10.1016\/j.jtho.2023.02.016_bib36","doi-asserted-by":"crossref","first-page":"S2198","DOI":"10.21037\/jtd.2018.06.118","article-title":"ALK inhibitors and checkpoint blockade: a cautionary tale of mixing oil with water?","volume":"10","author":"Patel","year":"2018","journal-title":"J\u00a0Thorac Dis"},{"key":"10.1016\/j.jtho.2023.02.016_bib37","doi-asserted-by":"crossref","first-page":"3836","DOI":"10.1200\/JCO.2008.20.8355","article-title":"Efficacy and safety of axitinib in patients with advanced non\u2013small-cell lung cancer: results from a phase II study","volume":"27","author":"Schiller","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2023.02.016_bib38","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3892\/mco.2017.1282","article-title":"A\u00a0retrospective study of docetaxel and bevacizumab as a second- or later-line chemotherapy for non-small cell lung cancer","volume":"7","author":"Kurishima","year":"2017","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.jtho.2023.02.016_bib39","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(14)60845-X","article-title":"Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial","volume":"384","author":"Garon","year":"2014","journal-title":"Lancet"},{"issue":"suppl 5","key":"10.1016\/j.jtho.2023.02.016_bib40","first-page":"S949","article-title":"1194MO - Canakinumab (CAN)+ docetaxel (DTX) for the second-or third-line (2\/3L) treatment of advanced non-small cell lung cancer (NSCLC): CANOPY-2 phase III results","volume":"32","author":"Paz-Ares","year":"2021","journal-title":"Ann Oncol"},{"issue":"suppl","key":"10.1016\/j.jtho.2023.02.016_bib41","doi-asserted-by":"crossref","first-page":"S1001","DOI":"10.1016\/j.jtho.2021.08.312","article-title":"P10. 07 Real-world us treatment patterns and clinical outcomes in advanced NSCLC after prior platinum chemotherapy and immunotherapy","volume":"16","author":"Smith","year":"2021","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2023.02.016_bib42","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1200\/JCO.22.00912","article-title":"Phase II randomized study of ramucirumab and pembrolizumab versus standard of care in advanced non\u2013small-cell lung cancer previously treated with immunotherapy\u2014lung-MAP S1800A","volume":"40","author":"Reckamp","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2023.02.016_bib43","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1158\/2159-8290.CD-18-0099","article-title":"STK11\/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma","volume":"8","author":"Skoulidis","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2023.02.016_bib44","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1158\/2159-8290.CD-20-1543","article-title":"Resistance to durvalumab and durvalumab plus tremelimumab is associated with functional STK11 mutations in patients with non\u2013small cell lung cancer and is reversed by STAT3 knockdown","volume":"11","author":"Pore","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2023.02.016_bib45","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1634\/theoncologist.2019-0244","article-title":"Tumor mutational burden as a predictive biomarker for response to immune checkpoint inhibitors: a review of current evidence","volume":"25","author":"Klempner","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.jtho.2023.02.016_bib46","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1093\/jnci\/djab068","article-title":"Predictive biomarkers: progress on the road to personalized cancer immunotherapy","volume":"113","author":"Emens","year":"2021","journal-title":"J\u00a0Natl Cancer Inst"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086423001582?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086423001582?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:51:34Z","timestamp":1761562294000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086423001582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":44,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S1556086423001582"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2023.02.016","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2023.02.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 International Association for the Study of Lung Cancer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}